IFxHu-20 is under clinical development by TuHURA Biosciences and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase I drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IFxHu-20’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IFxHu-20 overview
IFx-Hu20 is under development for the treatment of cutaneous melanoma, Merkel cell carcinoma, non-melanoma skin cancers, ovarian cancer, triple-negative breast cancer and cutaneous squamous cell carcinoma. The therapeutic candidate is administered through intralesional route. It comprises of plasmid DNA coding for Emm55 Streptococcal antigen. It is developed based on ImmuneFx technology. The therapeutic candidate is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer.
It was also under development for the treatment of colorectal cancer, gastric cancer and head and neck cancer, basal cell carcinoma.
TuHURA Biosciences overview
TuHURA Biosciences Inc (TuHURA Biosciences) is a company that focuses on developing innovative technologies to enhance the effectiveness of cancer immunotherapies. The company offers advancing proprietary technologies to address resistance to cancer treatments. Its pipeline products include IFx-2.0 which is a personalized cancer vaccine; IFx-3.0 a personalized cancer vaccine delivered intravenously; Nal – Anti TIGIT which is a bi-functional antibody drug conjugates (ADCs) overcoming acquired resistance to checkpoint inhibitors and cellular therapies. The company has operations in the US. TuHURA Biosciences is headquartered in Tampa, Florida, the US.
For a complete picture of IFxHu-20’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
